Company news

Cocrystal Pharma, Inc. news in 2021

Cocrystal Pharma, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Cocrystal Pharma’s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

December 21, 2021

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

December 1, 2021

Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021

November 30, 2021

Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones

November 14, 2021

Cocrystal Pharma’s SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses

November 7, 2021

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

October 31, 2021

Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021

October 20, 2021

Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021

October 13, 2021

Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza

October 5, 2021

Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 6, 2021

Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates

August 15, 2021

Cocrystal Pharma’s SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants

July 28, 2021

Cocrystal Joins Russell Microcap® Index

June 27, 2021

Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

June 22, 2021

Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

June 13, 2021

Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox

May 27, 2021

Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update

May 16, 2021

Cocrystal Pharma Announces Closing of $40 Million Bought Deal

May 6, 2021

Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock

May 3, 2021

Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs

May 2, 2021

Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones

March 16, 2021

Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX

March 9, 2021

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement

January 18, 2021

Decks in 2021